Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Advances in use of immunomodulatory agents—a rheumatology perspective

Nature Reviews Gastroenterology & Hepatology volume 12, pages 363–368 (2015)Cite this article

Subjects

Abstract

With the advent of biologic agents such as TNF inhibitors, the treatment paradigm for autoimmune systemic inflammatory diseases has progressed tremendously. Despite some distinct treatments, similarities exist in several aspects of the treatment of autoimmune inflammatory diseases such as rheumatoid arthritis (RA), IBD and psoriasis. With a so-called treat-to-target strategy aiming at remission, the intensive and early application of disease-modifying antirheumatic drugs within a 'window of opportunity', and in combination with TNF inhibitors, has become the overarching principle of RA therapy. In this Perspective, the concept of treatment approaches using immunomodulatory agents and the latest advances of therapies in autoimmune systemic inflammatory diseases, especially RA, are overviewed from a rheumatology perspective to provide insights into possible approaches to the treatment of inflammatory gastrointestinal disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Available and possible future therapies for rheumatoid arthritis and other rheumatic diseases, and their targets.

Similar content being viewed by others

References

  1. Pincus, T. Rheumatoid arthritis: a medical emergency? Scand. J. Rheumatol. Suppl. 100, 21–30 (1994).

    Article  CAS  Google Scholar 

  2. Kaye, R. L. & Pemberton, R. E. Treatment of rheumatoid arthritis: a review including newer and experimental anti-inflammatory agents. Arch. Intern. Med. 136, 1023–1028 (1976).

    Article  CAS  Google Scholar 

  3. Moreland, L. W. & Bridges, S. L. Jr. Early rheumatoid arthritis: a medical emergency? Am. J. Med. 111, 498–500 (2001).

    Article  CAS  Google Scholar 

  4. Lard, L. R. et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med. 111, 446–451 (2001).

    Article  CAS  Google Scholar 

  5. Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature 423, 356–361 (2003).

    Article  CAS  Google Scholar 

  6. Singh, J. A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64, 625–639 (2012).

    Article  CAS  Google Scholar 

  7. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492–509 (2014).

    Article  CAS  Google Scholar 

  8. Colombel, J. F., Feagan, B. G., Sandborn, W. J., Van Assche, G. & Robinson, A. M. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm. Bowel Dis. 18, 349–358 (2012).

    Article  Google Scholar 

  9. Goekoop-Ruiterman, Y. P. et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 146, 406–415 (2007).

    Article  Google Scholar 

  10. Kameda, H. et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J. Rheumatol. 38, 1585–1592 (2011).

    Article  CAS  Google Scholar 

  11. Breedveld, F. C. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006).

    Article  CAS  Google Scholar 

  12. Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004).

    Article  CAS  Google Scholar 

  13. Saag, K. G. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762–784 (2008).

    Article  CAS  Google Scholar 

  14. Bendele, A. M. et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. 43, 2648–2659 (2000).

    Article  CAS  Google Scholar 

  15. Genovese, M. C. et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50, 1412–1419 (2004).

    Article  CAS  Google Scholar 

  16. Weinblatt, M. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 66, 228–234 (2007).

    Article  CAS  Google Scholar 

  17. Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932–1939 (1999).

    Article  CAS  Google Scholar 

  18. van Nies, J. A. et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann. Rheum. Dis. 73, 861–870 (2014).

    Article  CAS  Google Scholar 

  19. Genovese, M. C. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46, 1443–1450 (2002).

    Article  CAS  Google Scholar 

  20. Emery, P. et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372, 375–382 (2008).

    Article  CAS  Google Scholar 

  21. Smolen, J. S. et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 54, 702–710 (2006).

    Article  CAS  Google Scholar 

  22. Gonzalez-Alvaro, I. et al. Biomarkers predicting a need for intensive treatment in patients with early arthritis. Curr. Pharm. Des. 21, 170–181 (2015).

    Article  CAS  Google Scholar 

  23. Solomon, D. H. et al. Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol. 66, 775–782 (2014).

    Article  Google Scholar 

  24. Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263–269 (2004).

    Article  Google Scholar 

  25. Verstappen, S. M. et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 66, 1443–1449 (2007).

    Article  CAS  Google Scholar 

  26. Gerstein, H. C. et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 364, 818–828 (2011).

    Article  CAS  Google Scholar 

  27. Felson, D. T. et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann. Rheum. Dis. 70, 404–413 (2011).

    Article  Google Scholar 

  28. Anandarajah, A. et al. Patients with rheumatoid arthritis in clinical remission manifest persistent joint inflammation on histology and imaging studies. J. Rheumatol. 41, 2153–2160 (2014).

    Article  Google Scholar 

  29. van der Heijde, D. Quantification of radiological damage in inflammatory arthritis: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Best Pract. Res. Clin. Rheumatol. 18, 847–860 (2004).

    Article  Google Scholar 

  30. Ostergaard, M. et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J. Rheumatol. 30, 1385–1386 (2003).

    PubMed  Google Scholar 

  31. Castrejon, I. & Pincus, T. Patient self-report outcomes to guide a treat-to-target strategy in clinical trials and usual clinical care of rheumatoid arthritis. Clin. Exp. Rheumatol. 30, S50–S55 (2012).

    PubMed  Google Scholar 

  32. Burmester, G. R., Feist, E. & Dorner, T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 10, 77–88 (2014).

    Article  CAS  Google Scholar 

  33. Kavanaugh, A. et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann. Rheum. Dis. 73, 1000–1006 (2014).

    Article  CAS  Google Scholar 

  34. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).

    Article  CAS  Google Scholar 

  35. Kavanaugh, A. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73, 1020–1026 (2014).

    Article  CAS  Google Scholar 

  36. US National Library of Medicine. ClinicalTrials.gov[online], (2012).

  37. US National Library of Medicine. ClinicalTrials.gov[online], (2012).

  38. US National Library of Medicine. ClinicalTrials.gov[online], (2014).

  39. US National Library of Medicine. ClinicalTrials.gov[online], (2013).

  40. US National Library of Medicine. ClinicalTrials.gov[online], (2015).

  41. US National Library of Medicine. ClinicalTrials.gov[online], (2012).

  42. O'Shea, J. J., Laurence, A. & McInnes, I. B. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat. Rev. Rheumatol. 9, 173–182 (2013).

    Article  Google Scholar 

  43. Kitahara, K. & Kawai, S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr. Opin. Rheumatol. 19, 238–245 (2007).

    Article  CAS  Google Scholar 

  44. Lee, E. B. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370, 2377–2386 (2014).

    Article  Google Scholar 

  45. Emery, P. et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203993.

  46. Harrold, L. R. et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann. Rheum. Dis. 74, 430–436 (2015).

    Article  CAS  Google Scholar 

  47. Keiserman, M. et al. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Rev. Clin. Immunol. 10, 1049–1057 (2014).

    Article  CAS  Google Scholar 

  48. Pal, S. K., Figlin, R. A. & Reckamp, K. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol. Cancer Ther. 9, 1931–1944 (2010).

    Article  CAS  Google Scholar 

  49. Higgins, M. J. & Baselga, J. Targeted therapies for breast cancer. J. Clin. Invest. 121, 3797–3803 (2011).

    Article  CAS  Google Scholar 

  50. Sparks, J. A. & Costenbader, K. H. Genetics, environment, and gene-environment interactions in the development of systemic rheumatic diseases. Rheum. Dis. Clin. North Am. 40, 637–657 (2014).

    Article  Google Scholar 

  51. Schett, G., Elewaut, D., McInnes, I. B., Dayer, J. M. & Neurath, M. F. How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat. Med. 19, 822–824 (2013).

    Article  CAS  Google Scholar 

  52. Gabay, C., Lamacchia, C. & Palmer, G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6, 232–241 (2010).

    Article  CAS  Google Scholar 

  53. Alten, R. et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res. Ther. 10, R67 (2008).

    Article  Google Scholar 

  54. Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443–2452 (2008).

    Article  CAS  Google Scholar 

  55. Kremer, J. M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 63, 609–621 (2011).

    Article  CAS  Google Scholar 

  56. Sieper, J., Porter-Brown, B., Thompson, L., Harari, O. & Dougados, M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann. Rheum. Dis. 73, 95–100 (2014).

    Article  CAS  Google Scholar 

  57. Dougados, M. et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann. Rheum. Dis. 73, 803–809 (2014).

    Article  CAS  Google Scholar 

  58. Langley, R. G. et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N. Engl. J. Med. 371, 326–338 (2014).

    Article  Google Scholar 

  59. Genovese, M. C. et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J. Rheumatol. 41, 414–421 (2014).

    Article  CAS  Google Scholar 

  60. Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).

    Article  CAS  Google Scholar 

  61. Tanaka, Y. et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann. Rheum. Dis. 74, 389–395 (2015).

    Article  CAS  Google Scholar 

  62. Smolen, J. S. et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381, 918–929 (2013).

    Article  CAS  Google Scholar 

  63. Smolen, J. S. et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 383, 321–332 (2014).

    Article  CAS  Google Scholar 

  64. Emery, P. et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N. Engl. J. Med. 371, 1781–1792 (2014).

    Article  CAS  Google Scholar 

  65. Kavanaugh, A. & Smolen, J. S. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials. Clin. Exp. Rheumatol. 31, S19–S21 (2013).

    PubMed  Google Scholar 

  66. Yoo, D. H. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert Rev. Clin. Immunol. 10, 981–983 (2014).

    Article  CAS  Google Scholar 

  67. U.S. Food and Drug Administration. Biosimilars. FDA [online], (2015).

  68. Euopean Medicines Agency. Biosimilar medicines. European Medicines Agency [online], (2015).

  69. Burmester, G. R., Panaccione, R., Gordon, K. B., McIlraith, M. J. & Lacerda, A. P. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann. Rheum. Dis. 72, 517–524 (2013).

    Article  CAS  Google Scholar 

  70. Kavanaugh, A. et al. Proceedings from the ACR Reproductive Health Summit: the management of fertility, pregnancy and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res. (Hoboken) 67, 313–325 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Busan Paik Hospital, Inje University, Gaegum-Dong, Bokji-ro 75, Busanjin-Gu, 614-735, Busan, South Korea

    Minyoung Her

  2. Division of Rheumatology, Allergy, and Immunology, The University of California, San Diego, 9500 Gilman Drive, Mail Code 0943, La Jolla, 92037, CA, USA

    Arthur Kavanaugh

Authors
  1. Minyoung Her
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arthur Kavanaugh
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors made equal contributions to researching data, discussing the content and writing the manuscript. A.K. reviewed and edited the manuscript before submission.

Corresponding author

Correspondence to Arthur Kavanaugh.

Ethics declarations

Competing interests

A.K. has conducted clinical trials sponsored and/or provided consultation to: AstraZeneca; AbbVie; Amgen; Bristol–Myers Squibb; Celgene; Eli Lilly; Janssen; Pfizer; Roche; UCB Pharma. M.H. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Her, M., Kavanaugh, A. Advances in use of immunomodulatory agents—a rheumatology perspective. Nat Rev Gastroenterol Hepatol 12, 363–368 (2015). https://doi.org/10.1038/nrgastro.2015.65

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2015.65

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing